Compare BKU & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | DMAC |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 441.6M |
| IPO Year | 2011 | N/A |
| Metric | BKU | DMAC |
|---|---|---|
| Price | $45.22 | $8.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $42.73 | $15.50 |
| AVG Volume (30 Days) | ★ 1.0M | 584.7K |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 44.85 | N/A |
| EPS | ★ 3.54 | N/A |
| Revenue | ★ $1,016,093,000.00 | N/A |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $12.80 | ★ N/A |
| Revenue Growth | ★ 10.45 | N/A |
| 52 Week Low | $28.21 | $3.19 |
| 52 Week High | $46.92 | $10.42 |
| Indicator | BKU | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 64.89 | 53.39 |
| Support Level | $45.33 | $8.00 |
| Resistance Level | $46.33 | $10.14 |
| Average True Range (ATR) | 0.94 | 0.70 |
| MACD | -0.11 | -0.12 |
| Stochastic Oscillator | 44.89 | 25.76 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.